Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

Core Insights - Mainz Biomed announced positive topline results from a feasibility study for a non-invasive blood-based screening test for early detection of pancreatic cancer, achieving 100% sensitivity and 95% specificity in a cohort of 30 subjects [1][2][3] Group 1: Study Results - The study confirmed the clinical accuracy of licensed proprietary biomarkers from Liquid Biosciences, with the leading panel achieving 100% sensitivity and 95% specificity [1] - Previous datasets demonstrated strong performance with 95% sensitivity and 98% specificity, reinforcing confidence in the biomarker panel's robustness [2] - The algorithm successfully detected precancerous lesions, allowing for earlier intervention and monitoring of at-risk individuals [3] Group 2: Future Plans - Mainz Biomed plans to conduct a larger clinical study to finalize biomarker selection using banked retrospective samples, evaluating performance across different stages of pancreatic cancer [4] - A validation study using a larger cohort and Polymerase Chain Reaction (PCR) technology is intended to optimize the test for clinical utility and prepare for potential FDA submission [5] - The pancreatic cancer project aligns with the company's broader strategy to develop accessible molecular diagnostics for early cancer detection in areas with limited screening tools [5]